Nocturnal Hypoglycemia in Advanced CKD - and a Reassuring A1c
A 67-year-old man with 18 years of type 2 diabetes and an eGFR of 26 mL/min/1.73 m² has an A1c of 7.2%. He takes glyburide 10 mg twice daily, metformin 500 mg twice daily, and insulin glargine 20 units at bedtime. In the past month he has had three episodes of hypoglycemia, one with a glucose of 38 mg/dL requiring paramedics, all between 2 and 4 AM. He has unintentionally lost 5 kg and reports early satiety. Hemoglobin is 10.2 g/dL with an MCV of 86 fL, albumin 3.2 g/dL, and he has no known bleeding source. He asks whether his A1c means he is doing well.
1. Which of his medications should be stopped or changed, and why?
Read the worked answer
Stop glyburide. It is a long-acting sulfonylurea whose active metabolites accumulate in CKD, producing prolonged, recurrent, and sometimes fatal hypoglycemia. In advanced CKD, sulfonylurea-induced hypoglycemia often requires sustained dextrose infusion and may be treated with octreotide (which suppresses insulin secretion) when dextrose alone fails. Glipizide would be safer than glyburide but is not a good choice in someone who has already had severe events.
Stop metformin. At an eGFR of 26 it should not be continued (the FDA label contraindicates use below 30); the risk is lactic acidosis, and the marginal benefit is small here.
Reduce basal insulin by roughly 20% - from 20 units to about 15–16 units - because falling GFR reduces insulin clearance. The 38 mg/dL event requiring paramedics indicates a high-risk pattern, so also review injection technique, bedtime carbohydrate intake, and any doses given around poor oral intake. Reconfirm with a continuous glucose monitor or a 3 AM fingerstick rather than relying on symptoms.
A reasonable replacement is linagliptin (no renal dose adjustment, low hypoglycemia risk) or a DPP-4 inhibitor/GLP-1 receptor agonist; dapagliflozin can be initiated for cardiorenal indications at this eGFR but gives little glycemic benefit and warrants sick-day counseling.
2. How should the A1c of 7.2% be interpreted, and what glycemic target is appropriate?
Read the worked answer
The A1c is likely falsely low and should not be trusted at face value. Normocytic anemia, and CKD generally, shorten red-cell survival and reduce the time available for glycation; recent transfusion, ESA use, and iron deficiency all distort the result further. An A1c of 7.2% is therefore compatible with considerably worse average glycemia - and, importantly, with severe excursions in both directions.
Targets: in advanced CKD with significant comorbidity and a documented history of severe hypoglycemia, a reasonable A1c goal is roughly 7.5–8.0%, with the higher end favored when hypoglycemia risk dominates. The dominant principle is that the risk of a severe hypoglycemic event outweighs the benefit of a lower A1c in this patient.
Measure glycemia differently: continuous glucose monitoring, or at minimum structured fingerstick profiles including a 3 AM value, plus review of any meter downloads. Estimate time below range (goal under 4%, and under 1% below 54 mg/dL). Educate the patient and family on glucagon use.
Document that the A1c is unreliable and state the target explicitly, so that a future clinician does not intensify therapy based on a misleading number.
3. What is your approach to the weight loss and early satiety?
Read the worked answer
Do not assume this is uremia or poor diabetes control. Unintentional weight loss of 5 kg with early satiety in a 67-year-old warrants a structured evaluation.
- Medication effect: metformin and any GLP-1 receptor agonist cause weight loss and satiety - review the full list. If a GLP-1 agent is present, this is a likely contributor, but it does not exclude the alternatives.
- Gastroparesis: long-standing diabetes with early satiety and erratic absorption would also explain the hypoglycemia pattern. Consider a gastric-emptying study if symptoms persist after medication changes, and note that gastroparesis makes insulin timing unreliable.
- Malignancy: age, weight loss, and anemia should prompt at least age-appropriate colorectal cancer screening status, a careful GI history, and consideration of cross-sectional imaging or upper endoscopy. Pancreatic disease is a particular concern given the combination of weight loss, new glycemic instability, and diabetes of long duration.
- Others: depression, dentition, malabsorption, chronic infection, and thyroid disease (check TSH).
Iron studies and a hemolysis workup are reasonable for the anemia, both because it distorts the A1c and because it may point to the underlying process. Arrange close follow-up rather than a single visit - the trajectory over 4–8 weeks is often more informative than any single test.